NCT01165723View on ClinicalTrials.gov

A Clinical Study Evaluating The Safety And Tolerability Of PF-04427429 In Healthy Adult Volunteers. The Pharmacokinetics And Pharmacodynamics Of PF-04427429 Will Also Be Investigated

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions
Healthy
Interventions
BIOLOGICAL

PF-04427429

Intravenous dosing of 30mg on day 1 and one other day to be determined up to day 30

BIOLOGICAL

PF-04427429

Intravenous dosing of 30mg on day 1 and one other day to be determined up to day 30

Trial Locations (1)

B-1070

Pfizer Investigational Site, Brussels

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01165723 - A Clinical Study Evaluating The Safety And Tolerability Of PF-04427429 In Healthy Adult Volunteers. The Pharmacokinetics And Pharmacodynamics Of PF-04427429 Will Also Be Investigated | Biotech Hunter | Biotech Hunter